Treatment of oral leukoplakia with beta-carotene

S. Toma, S. Benso, E. Albanese, R. Palumbo, E. Cantoni, G. Nicolò, P. Mangiante

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Over the past few years, beta-carotene has progressively gained ground as a drug chosen in the treatment of oral leukoplakias, thus making it possible to reduce the use of 13-m-retinoic acid, which was shown by many studies to be highly toxic while beta-carotene has proved to have no significant side effects and hence to be much more suitable in oral premalignancy. In 1989, a phase II study of patients showing oral leukoplakias and treated with beta-carotene (90 mg/day) was begun. A total of 23 patients (aged between 17 and 85) were included in the study and 18 (8 male and 10 female) were evaluated. Eight patients (44.4%) had objective responses (6 complete, 2 partial). Four CR and a PR appeared unexpectedly within 2-7 months after the end of the therapy. The lesions were macroscopically and histologically examined at entry; in the evaluated patients, two types of alterations were found: atypical hyperplasia (16 patients) and dysplasia (2 patients). No signs of significant toxicity were detected; only in 1 patient treatment had to be interrupted for I week. The results of this study show the fair efficacy of beta-carotene against oral leukoplakias, but further confirmations through controlled clinical studies are needed.

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalOncology
Volume49
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Oral Leukoplakia
beta Carotene
Therapeutics
Poisons
Tretinoin
Hyperplasia

Keywords

  • Cellular differentiation
  • Chemoprevention
  • Oral leukoplakia
  • ²-carotene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Toma, S., Benso, S., Albanese, E., Palumbo, R., Cantoni, E., Nicolò, G., & Mangiante, P. (1992). Treatment of oral leukoplakia with beta-carotene. Oncology, 49(2), 77-81. https://doi.org/10.1159/000227016

Treatment of oral leukoplakia with beta-carotene. / Toma, S.; Benso, S.; Albanese, E.; Palumbo, R.; Cantoni, E.; Nicolò, G.; Mangiante, P.

In: Oncology, Vol. 49, No. 2, 1992, p. 77-81.

Research output: Contribution to journalArticle

Toma, S, Benso, S, Albanese, E, Palumbo, R, Cantoni, E, Nicolò, G & Mangiante, P 1992, 'Treatment of oral leukoplakia with beta-carotene', Oncology, vol. 49, no. 2, pp. 77-81. https://doi.org/10.1159/000227016
Toma S, Benso S, Albanese E, Palumbo R, Cantoni E, Nicolò G et al. Treatment of oral leukoplakia with beta-carotene. Oncology. 1992;49(2):77-81. https://doi.org/10.1159/000227016
Toma, S. ; Benso, S. ; Albanese, E. ; Palumbo, R. ; Cantoni, E. ; Nicolò, G. ; Mangiante, P. / Treatment of oral leukoplakia with beta-carotene. In: Oncology. 1992 ; Vol. 49, No. 2. pp. 77-81.
@article{d267e1875cc84bf6826a15ef2e85a4e5,
title = "Treatment of oral leukoplakia with beta-carotene",
abstract = "Over the past few years, beta-carotene has progressively gained ground as a drug chosen in the treatment of oral leukoplakias, thus making it possible to reduce the use of 13-m-retinoic acid, which was shown by many studies to be highly toxic while beta-carotene has proved to have no significant side effects and hence to be much more suitable in oral premalignancy. In 1989, a phase II study of patients showing oral leukoplakias and treated with beta-carotene (90 mg/day) was begun. A total of 23 patients (aged between 17 and 85) were included in the study and 18 (8 male and 10 female) were evaluated. Eight patients (44.4{\%}) had objective responses (6 complete, 2 partial). Four CR and a PR appeared unexpectedly within 2-7 months after the end of the therapy. The lesions were macroscopically and histologically examined at entry; in the evaluated patients, two types of alterations were found: atypical hyperplasia (16 patients) and dysplasia (2 patients). No signs of significant toxicity were detected; only in 1 patient treatment had to be interrupted for I week. The results of this study show the fair efficacy of beta-carotene against oral leukoplakias, but further confirmations through controlled clinical studies are needed.",
keywords = "Cellular differentiation, Chemoprevention, Oral leukoplakia, ²-carotene",
author = "S. Toma and S. Benso and E. Albanese and R. Palumbo and E. Cantoni and G. Nicol{\`o} and P. Mangiante",
year = "1992",
doi = "10.1159/000227016",
language = "English",
volume = "49",
pages = "77--81",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Treatment of oral leukoplakia with beta-carotene

AU - Toma, S.

AU - Benso, S.

AU - Albanese, E.

AU - Palumbo, R.

AU - Cantoni, E.

AU - Nicolò, G.

AU - Mangiante, P.

PY - 1992

Y1 - 1992

N2 - Over the past few years, beta-carotene has progressively gained ground as a drug chosen in the treatment of oral leukoplakias, thus making it possible to reduce the use of 13-m-retinoic acid, which was shown by many studies to be highly toxic while beta-carotene has proved to have no significant side effects and hence to be much more suitable in oral premalignancy. In 1989, a phase II study of patients showing oral leukoplakias and treated with beta-carotene (90 mg/day) was begun. A total of 23 patients (aged between 17 and 85) were included in the study and 18 (8 male and 10 female) were evaluated. Eight patients (44.4%) had objective responses (6 complete, 2 partial). Four CR and a PR appeared unexpectedly within 2-7 months after the end of the therapy. The lesions were macroscopically and histologically examined at entry; in the evaluated patients, two types of alterations were found: atypical hyperplasia (16 patients) and dysplasia (2 patients). No signs of significant toxicity were detected; only in 1 patient treatment had to be interrupted for I week. The results of this study show the fair efficacy of beta-carotene against oral leukoplakias, but further confirmations through controlled clinical studies are needed.

AB - Over the past few years, beta-carotene has progressively gained ground as a drug chosen in the treatment of oral leukoplakias, thus making it possible to reduce the use of 13-m-retinoic acid, which was shown by many studies to be highly toxic while beta-carotene has proved to have no significant side effects and hence to be much more suitable in oral premalignancy. In 1989, a phase II study of patients showing oral leukoplakias and treated with beta-carotene (90 mg/day) was begun. A total of 23 patients (aged between 17 and 85) were included in the study and 18 (8 male and 10 female) were evaluated. Eight patients (44.4%) had objective responses (6 complete, 2 partial). Four CR and a PR appeared unexpectedly within 2-7 months after the end of the therapy. The lesions were macroscopically and histologically examined at entry; in the evaluated patients, two types of alterations were found: atypical hyperplasia (16 patients) and dysplasia (2 patients). No signs of significant toxicity were detected; only in 1 patient treatment had to be interrupted for I week. The results of this study show the fair efficacy of beta-carotene against oral leukoplakias, but further confirmations through controlled clinical studies are needed.

KW - Cellular differentiation

KW - Chemoprevention

KW - Oral leukoplakia

KW - ²-carotene

UR - http://www.scopus.com/inward/record.url?scp=0026562572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026562572&partnerID=8YFLogxK

U2 - 10.1159/000227016

DO - 10.1159/000227016

M3 - Article

VL - 49

SP - 77

EP - 81

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -